Browse COL3A1

Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix
Domain PF01410 Fibrillar collagen C-terminal domain
PF01391 Collagen triple helix repeat (20 copies)
PF00093 von Willebrand factor type C domain
Function

Collagen type III occurs in most soft connective tissues along with type I collagen. Involved in regulation of cortical development. Is the major ligand of ADGRG1 in the developing brain and binding to ADGRG1 inhibits neuronal migration and activates the RhoA pathway by coupling ADGRG1 to GNA13 and possibly GNA12.

> Gene Ontology
 
Biological Process GO:0001101 response to acid chemical
GO:0001501 skeletal system development
GO:0001764 neuron migration
GO:0002683 negative regulation of immune system process
GO:0007160 cell-matrix adhesion
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0007229 integrin-mediated signaling pathway
GO:0007265 Ras protein signal transduction
GO:0007266 Rho protein signal transduction
GO:0007507 heart development
GO:0007517 muscle organ development
GO:0007568 aging
GO:0007596 blood coagulation
GO:0007599 hemostasis
GO:0009314 response to radiation
GO:0009612 response to mechanical stimulus
GO:0010721 negative regulation of cell development
GO:0018149 peptide cross-linking
GO:0021537 telencephalon development
GO:0021543 pallium development
GO:0021987 cerebral cortex development
GO:0030168 platelet activation
GO:0030198 extracellular matrix organization
GO:0030199 collagen fibril organization
GO:0030336 negative regulation of cell migration
GO:0030574 collagen catabolic process
GO:0030900 forebrain development
GO:0031589 cell-substrate adhesion
GO:0032963 collagen metabolic process
GO:0035023 regulation of Rho protein signal transduction
GO:0035025 positive regulation of Rho protein signal transduction
GO:0035904 aorta development
GO:0035909 aorta morphogenesis
GO:0040013 negative regulation of locomotion
GO:0043062 extracellular structure organization
GO:0043200 response to amino acid
GO:0043206 extracellular fibril organization
GO:0043588 skin development
GO:0044236 multicellular organism metabolic process
GO:0044243 multicellular organism catabolic process
GO:0044259 multicellular organismal macromolecule metabolic process
GO:0046578 regulation of Ras protein signal transduction
GO:0046579 positive regulation of Ras protein signal transduction
GO:0048514 blood vessel morphogenesis
GO:0048565 digestive tract development
GO:0048644 muscle organ morphogenesis
GO:0048745 smooth muscle tissue development
GO:0048844 artery morphogenesis
GO:0050768 negative regulation of neurogenesis
GO:0050777 negative regulation of immune response
GO:0050817 coagulation
GO:0050878 regulation of body fluid levels
GO:0051056 regulation of small GTPase mediated signal transduction
GO:0051057 positive regulation of small GTPase mediated signal transduction
GO:0051271 negative regulation of cellular component movement
GO:0051961 negative regulation of nervous system development
GO:0055123 digestive system development
GO:0060414 aorta smooth muscle tissue morphogenesis
GO:0060415 muscle tissue morphogenesis
GO:0060537 muscle tissue development
GO:0060840 artery development
GO:0071229 cellular response to acid chemical
GO:0071230 cellular response to amino acid stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0097435 fibril organization
GO:2000146 negative regulation of cell motility
GO:2001222 regulation of neuron migration
GO:2001223 negative regulation of neuron migration
Molecular Function GO:0005178 integrin binding
GO:0005201 extracellular matrix structural constituent
GO:0019838 growth factor binding
GO:0046332 SMAD binding
GO:0048407 platelet-derived growth factor binding
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005581 collagen trimer
GO:0005583 fibrillar collagen trimer
GO:0005586 collagen type III trimer
GO:0005788 endoplasmic reticulum lumen
GO:0044420 extracellular matrix component
GO:0098643 banded collagen fibril
GO:0098644 complex of collagen trimers
> KEGG and Reactome Pathway
 
KEGG hsa04611 Platelet activation
hsa04974 Protein digestion and absorption
Reactome R-HSA-2022090: Assembly of collagen fibrils and other multimeric structures
R-HSA-2173782: Binding and Uptake of Ligands by Scavenger Receptors
R-HSA-1650814: Collagen biosynthesis and modifying enzymes
R-HSA-8948216: Collagen chain trimerization
R-HSA-1474290: Collagen formation
R-HSA-1474244: Extracellular matrix organization
R-HSA-3000480: Scavenging by Class A Receptors
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between COL3A1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of COL3A1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of COL3A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.3350.0346
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.0750.59
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7750.762
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-1.0410.0961
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.0460.796
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0330.843
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3530.681
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0210.994
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.5410.867
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.2280.668
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 283.2580.406
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2360.32
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of COL3A1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141721.45.915.50.304
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103300300.528
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277325.913.712.20.228
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275925.915.310.60.248
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.611.816.80.257
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.818.212.60.649
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.214.8-1.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.223.1-4.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.27.1-0.91
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of COL3A1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of COL3A1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by COL3A1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of COL3A1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of COL3A1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between COL3A1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCOL3A1
Namecollagen, type III, alpha 1
Aliases EDS4A; Ehlers-Danlos syndrome type IV, autosomal dominant; alpha1 (III) collagen; collagen, fetal; Collagen ......
Chromosomal Location2q32.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting COL3A1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting COL3A1.
ID Name Drug Type Targets #Targets
DB00048Collagenase clostridium histolyticumBiotechCOL1A1, COL1A2, COL2A1, COL3A14